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Transcranial direct current stimulation (tDCS) is a novel non-invasive neuromodulatory
method that influences neuronal firing rates and excitability of neuronal circuits in the
brain. tDCS has been shown to relieve Major Depressive Disorder (MDD) in the general
population, suggesting its potential for other vulnerable populations with high MDD preva-
lence.Aims:This study evaluated the feasibility, safety, acceptability, and clinical outcomes
of a 2-week tDCS antidepressant treatment in HIV-MDD co-diagnosed patients, and the
feasibility of collecting serum and saliva for analysis of immunity biomarkers. Methods:Ten
enrolled patients underwent baseline evaluation and started the tDCS treatment (Monday–
Friday for 2 weeks) delivered with Phoresor II 850 PM for 20 min at 2 mA at each visit, using
two saline-soaked sponge electrodes placed over the F3 position of EEG 10–20 system and
the contralateral supraorbital region. Outcome measures were collected at baseline, after
the last tDCS and 2 weeks later. A quantitative microarray (Ray Bio Tech Inc.) for TH1/TH2
cytokines was used for saliva and plasma analysis. Results: Analyzable outcome-data
were obtained from eight subjects. Depression scores significantly decreased (p<0.0005)
after the treatment. No serious adverse events occurred. Several transient minor AEs and
occasional changes of blood pressure and heart rate were noted. Mini-mental state exam-
ination scores remained unchanged or increased after the treatment. All subjects were
highly satisfied with the protocol and treatment results and described the desire to find
new treatments for HIV-MDD as motivating participation. Conclusion: Findings support
feasibility and clinical potential of tDCS for HIV-MDD patients, and justify larger-sample,
sham-controlled trials.
Keywords: transcranial direct current stimulation, HIV, major depressive disorder, neuromodulation
INTRODUCTION
Transcranial direct current stimulation (tDCS) has been shown
to be a powerful technique for non-invasive neuromodulation
(Nitsche and Paulus, 2010). The primary mechanism of tDCS is a
subthreshold modulation of neuronal resting membrane potential
which induces a polarity-dependent modification of N -Methyl-d-
aspartate (NMDA) receptor function (Antal et al., 2010; Nitsche
and Paulus, 2010) that plays a role in neuroplasticity. Some of
tDCS induced changes occurs immediately during the stimulation
(so called intra-tDCS changes), while others occur later as short-
lasting or long-lasting after-effects (Nitsche and Paulus, 2010).
As suggested by pharmacological studies (Liebetanz et al., 2002;
Nitsche et al., 2004), the intra-tDCS effects depend on the activ-
ity of sodium and calcium channels but not on efficacy changes
of NMDA and gamma-aminobutyric acid (GABA) receptors, and
thus are probably generated solely by polarity specific shifts of
resting membrane potential. However, the after-effects have been
shown to be protein synthesis dependent (Gartside, 1968; Hattori
et al., 1990; Nitsche and Paulus, 2010) and also involve modula-
tions of NMDA receptors efficacy. (Liebetanz et al., 2002; Nitsche
et al., 2005; Nitsche and Paulus, 2010).
In several randomized controlled studies utilizing 2 or 4 week
tDCS treatment protocols, tDCS delivered over the dorsolateral
prefrontal cortex (DLPFC) was shown to safely relieve Major
Depressive Disorder (MDD) in the general population (Fregni
et al., 2006; Boggio et al., 2008a; Rigonatti et al., 2008; Murphy
et al., 2009; Nitsche et al., 2009; Kalu et al., 2012). Although the
mechanisms of tDCS antidepressant effect are not fully under-
stood, it is reasonable to assume that tDCS might have induced
a change in the DLPFC activity which is highly relevant to
alterations of mood-related neuronal networks (Boggio et al.,
2008a).
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This suggests the clinical potential of tDCS treatment for other
vulnerable populations with high prevalence of MDD, such as per-
sons with HIV infection. Various estimates (McHorney et al., 1994;
Lyketsos, 1995; Boland, 1997; Stober et al., 1997; Chander et al.,
2006; Hartzell et al., 2008; Rabkin, 2008) suggest that up to 48% of
HIV-infected patients have MDD comorbidity. MDD accelerates
HIV disease progression, jeopardizes the completion of antiretro-
viral treatment and is a potent risk factor for transmission of the
virus to others (Wilson et al., 2007). Despite the fact that MDD
is the most common psychiatric disorder in HIV populations
after substance abuse (Rabkin, 2008), conventional antidepres-
sant treatments, such as medication or psychotherapy, leave many
patients with undertreated depressive symptoms (Lyketsos, 1995;
Chander et al., 2006; Hartzell et al., 2008). For treatment-resistant
depressed patients, depression is often lifelong and disabling and
represents a significant source of suffering, disruption in role func-
tioning, economic burden to society, and mortality (Gaynes et al.,
2008).
Although tDCS treatment may greatly improve the quality of
life of HIV patients suffering MDD, to our knowledge, no previous
tDCS study has included such patients. Therefore, we carried out
a quantitative and qualitative open-label pilot trial to evaluate the
safety, tolerability, acceptability, and clinical outcomes of a 2-week
tDCS treatment protocol to treat MDD in HIV-infected patients
and explore the feasibility of collecting serum and saliva cytokines
for future analysis. The purpose of the study was to determine
overall feasibility of the study protocol in an HIV patient-sample
and to provide initial data for sample size estimates and power for
a future, sham-controlled randomized trial (RCT).
MATERIALS AND METHODS
SUBJECTS
Ten adult subjects diagnosed with HIV and MDD who fully met
the following inclusion criteria participated in the study.
Inclusion Criteria comprised of the following: (i) Diagnosed
with HIV; (ii) MDD as measured by the Hamilton Depression
Rating Scale score at least >17 at the time of enrollment as well
as 1 week later at the time of the baseline; (iii) MDD as measured
by the Montgomery-Asberg Depression Rating Scale (MADRAS)
score at least>11 at the time of enrollment as well as at the baseline.
Subjects were excluded from participation if they met the
following exclusion criteria.
Exclusion Criteria: (i) Diagnosed with AIDS; (ii) Active
and/or history of schizophrenia, schizoaffective disorder, psy-
chosis, mental retardation, substance dependence, or abuse within
the past year (except nicotine), bipolar disorder, psychotic features,
amnesic disorder, dementia, delirium, or obsessive-compulsive
disorder; (iii) History of opportunistic infection affecting the
brain; (iv) Methadone treatment; (v) History of neurological
disorder or seizure (except induced by electroconvulsive ther-
apy, ECT), increased intracranial pressure, brain surgery, or head
trauma with loss of consciousness for >15 min, implanted elec-
tronic device, metal in the head; (vi) History of autoimmune,
endocrine, or vascular disorder, unstable cardiac disease, uncon-
trolled hypertension, or sleep apnea; (vii) Active suicidal intent;
(viii) Pregnancy; (ix) Unable to follow instructions or complete
assessment tools in English.
Participation in this study did not require any changes in the
patient’s medication regimen.
PROCEDURES
Overview
The protocol consisted of 12 study visits. At the initial visit, the
informed consent was obtained and patients were screened for
eligibility. Baseline values of outcome measures were established
at the initial visit and 1 week after the initial visit. The subjects
who fully met the inclusion criteria then started a 2-week course
of tDCS treatment (10 sessions, visits #2 – #11, Monday–Friday
for 2 weeks, each session consisting of 20 min of tDCS). Two
weeks after the last tDCS treatment, participants came for visit
#12 (Follow-up/Completion). The primary outcome measure was
safety; secondary outcomes were treatment benefits/clinical out-
comes, tolerability, acceptability, and patients’ satisfaction. The
outcome measurement time points were before the first tDCS
treatment, immediately after the last tDCS treatment and at the
follow-up visit which was conducted 2 weeks after the treatment.
Transcranial direct current stimulation
Transcranial direct current stimulation was delivered by trained
study personnel using the battery-operated device Phoresor II
Auto (Model No. PM850) with two saline-soaked sponge elec-
trodes of size 6 cm× 6 cm, with a rubber rim of 1 cm and sponge-
skin contact area of 5 cm× 5 cm. The anode was placed over the
left DLPFC as determined by the international EEG 10–20 clas-
sification (point F3), and the cathode was over the contralateral
supraorbital region. The current was delivered at the intensity of
2 mA for 20 min. These parameters of stimulation were success-
fully and safely used in many previous tDCS studies (Fregni et al.,
2006; Rigonatti et al., 2008; Knotkova et al., 2009) and were well
within safety limits. A detailed review of tDCS safety and para-
meters of stimulation-protocols in human subjects appear in Sun-
daram et al. (2009). The tDCS treatment course was considered
complete if the subject received at least 8 of 10 treatment sessions,
and if the two missed sessions were not on consecutive days.
Assessment methods
(a) The HamD (HamD-24) is the most widely used scale for
patient selection and follow-up in research studies of depres-
sion treatments. In this clinician-administered instrument,
the clinician chooses the best response to each of 24 items by
interviewing the patient and by observing the patient’s symp-
toms. Content includes symptoms of depression designated
in the Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition, text revision; DSM IV-TR) published
by the American Psychiatric Association. These include: low
mood, insomnia, agitation, anxiety and weight change. The
instrument is highly reliable (alpha= 0.87) when the clinician
uses the Structure Interview Guide for the Hamilton (SIGH;
Williams, 1998) as was done in this study.
(b) The Montgomery-Asberg Depression Rating Scale (MADRAS)
is a clinician-administered 10-item rating scale to assess the
severity of a patient’s depressive symptoms within the last
7 days. The items were taken from the 65-item Comprehensive
Psychopathological Rating Scale (CPRS) and were selected
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because of their sensitivity to change. The 10 selected items are
rated on a scale of 0–6 with anchors at 2-point intervals. The
interviewer is encouraged to use his or her observations of the
patient’s mental state as an additional source of information.
Total scores on the MADRAS range from 0 to 60. It has been
shown to have high inter-rater reliability (Spearman r = 0.94)
and good concurrent validity (r with HamD between 0.83 and
0.94; Davidson, 1986). We have used this psychometric tool
in addition to HamD because MADRAS offers an alternative
view of depressive illness, and may be more sensitive than
HamD to some depressive symptoms such as hypersomnia,
increased appetite, and concentration/indecision.
(c) Mini-Mental State Examination (MMSE ; Folstein et al., 1975)
is a widely used clinical instrument for quick detection of
cognitive impairment and assessing its severity, as well as for
monitoring cognitive changes over time. In this study, MMSE
was used as a part of the physical and mental evaluation of
subjects at the initial and at the completion visit.
(d) Patient’s Satisfaction Rating Scale is a combined 4-point (0–3)
scale for participants’ self-rating when answering the ques-
tion “How satisfied were you with the results of the tDCS
treatment?” 0= not at all; 1= a little bit; 2= a lot; 3= fully
satisfied.
(e) Patient’s Daily Records: Throughout the study, participants
kept at-home daily records (i.e., Daily Diaries) detailing con-
sumption of medications, and potential changes in health
status, including depression, pain, fatigue, and level of physical
activity.
(f) Monitoring of the adverse events (AEs) was performed
throughout the study using the following: direct contact of
study personnel with the participant at study visits, patient’s
daily diaries, regular phone calls from the study personnel
to the patient in the follow-up period. In addition, subjects
were instructed to notify the study personnel immediately if
any concerns or if any unexpected/sudden changes of health
occurred.
(g) Qualitative Interviews: Giorgi’s phenomenology (Giorgi,
1985) was the method used to describe the experiences of per-
sons undergoing tDCS for treatment of depression. In-person
audio-taped interviews were conducted at the completion visit
by an experienced qualitative researcher and were immedi-
ately transcribed verbatim. Interviews ranged from 30 min
to 1 h. Each participant was asked the open-ended question,
“Please tell me about your experience undergoing tDCS for
the treatment of depression.” Probes included the following
questions:“What was the experience like for you? What should
we continue to do and what should we change to make the
experience better for patients?” Themes were derived using
the constant comparative method (Thorne, 2000).
Others
One of the study aims was to determine the feasibility of collecting
serum and saliva samples for immunity-biomarkers assessment.
At the baseline, after the last tDCS treatment, and at the 2-week
follow-up visit, approximately 10 ml of plasma and 10 ml of whole
stimulated saliva were collected from subjects. Fluid samples were
pipetted in to.0 5 ml aliquots and immediately frozen at −80˚C,
to be prepared for analysis using RayBiotech TH1/TH2 anti-
body arrays. Results of the analysis will be reported in a separate
manuscript (in preparation).
Statistical analysis
To examine change in scores from pre- to post-tDCS adminis-
tration to 2-week follow-up, we conducted a repeated measures
analysis of variance using Predictive Analytics SoftWare (PASW)
Statistics, formerly known as Statistical Package for the Social
Sciences (SPSS) before it was acquired by IBM. First, analyses
determined whether the sphericity assumption was violated for
the analysis of the HamD and MADRAS scores. Helmert contrasts
were used when comparing (1) the pre-tDCS with the average of
the post-tDCS scores and the 2-week follow-up scores, and (2) the
post-tDCS scores and the 2-week follow-up scores.
Enrollment and the study procedures took place at Beth Israel
Medical Center, New York, NY. Biochemical analysis took place at
New York University, New York, NY. The study was approved by
the Institutional Review Boards at both institutions.
RESULTS
DEMOGRAPHIC CHARACTERISTICS AND SUBJECTS’ FLOW THROUGH
THE STUDY
The 10 study participants included 5 males and 5 females. Their
mean age was 52.5 (s.d.= 6.3) years, ranging from 38 to 59 years.
Almost all (9 of 10) were African American and one was non-
Hispanic Caucasian. Five were living with partners/spouses and
the others were separated, single, or never married, and living
alone. Although five of the participants had attended college, only
one was working (and on a part-time basis) and three of the
remaining nine were disabled. Scores on the MMSE examination
at the baseline were 28.0 (s.d.= 3.1), range 20–30, consistent with
the possibility of some mild cognitive impairment for a few of the
participants. Regarding their health, the 10 participants had been
living, on average, with HIV for 19.7 (s.d.= 4.1) years, range10–
26 years. All had co-morbid conditions, including three with
hepatitis C virus, three with hypertension,and five with a substance
abuse history. All had MDD as reflected in their scores of 17 or
greater on the HamD scale; 24.8 (5.8), range 17–34, and a score of
14 or greater on the MADRAS scale: 24.6 (7.4), range 14–34. Before
the study, none of the participants had ever had ECT, transcranial
magnetic stimulation (TMS), or tDCS treatment for their depres-
sion or other reasons. All subjects were taking HIV antiretroviral
medication. Besides that, several subjects were on stable regimens
of other medications, including the following CNS-acting agents:
Antidepressants – selective serotonin reuptake inhibitors [Celexa,
Zoloft] (subjects #3,6,9), tetracyclic antidepressants [Remeron]
(subject #4), and serotonin-norepinephrine reuptake inhibitors
[Effexor] (subject #4); Antipsychotics [Zyprexa, Seroquel, Risperi-
done] (subjects #4,9); Anticonvulsants [Depakote, Gabapentin]
(subjects #4,7); Sedative [Ambien] (subject #9); and Histamine
H2-receptor antagonists [Famotidine] (subject #3).
The 10 participants were recruited from a pool of 15 subjects
referred to the study. Of these, five were interested in participation
but could not participate for various reasons (e.g., could not make
commitment to 10 consecutive days of tDCS, lived far away). Ten
subjects provided informed consent and were screened according
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to the inclusion/exclusion criteria. All 10 subjects satisfied the
criteria and began the study protocol. Analyzable outcome-data
were obtained from 8 subjects; 7 of them completed all 10 treat-
ments, and 1 subject completed 8 of 10 treatments (missed
the last two treatments due to the death of a family member).
Two remaining subjects received only two initial treatment ses-
sions and did not continue due to conflicts with their personal
schedules.
CHANGES IN DEPRESSION SCALES BEFORE AND AFTER tDCS
ADMINISTRATION
Hamilton Depression Rating Scale
Hamilton Depression Rating Scale scores from the eight subjects at
baseline, immediately after the last tDCS treatment and at 2-week
follow-up averaged 26.3 (s.d.= 5.5), range 17–34; 9.9 (s.d.= 4.3),
range 5–17; and 7.6 (s.d.= 6.7), range 1–19, respectively. The mean
HamD scores differed significantly between time points according
to the repeated measures ANOVA: F(2, 14)= 94.555; p< 0.0005.
The sphericity assumption (see Materials and Methods) was not
violated for the HamD scores (p= 0.926). As can be seen in Table 1,
the pre-tDCS HamD scores were significantly higher than the aver-
age of the post-tDCS HamD scores and the 2-week follow-up
HamD scores [F(1, 7)= 174.112; p< 0.0005], indicating a highly
significant decrease in depression scores.
Notably, the post-tDCS HamD scores did not differ signifi-
cantly from the 2-week follow-up HamD scores [F(1, 7)= 2.498;
p= 0.158], indicating duration of the decrease of depressive
symptoms in the follow-up period.
MADRAS
On MADRAS, scores for the eight patients at baseline, immediately
after the last tDCS treatment and at 2-week follow-up averaged
26.8 (s.d.= 6.7), range 14–34; 11.3 (s.d.= 6.9), range 6–26; and
7.0 (s.d.= 7.4), range 0–20, respectively. According to the repeated
measures ANOVA, the mean MADRAS scores differed signifi-
cantly between time points: [F(2, 14)= 46.490; p< 0.0005]. The
sphericity assumption was not violated for the MADRAS scores
(p= 0.421). As can be seen in Table 2, the pre-tDCS MADRAS
scores were significantly higher than the average of the post-tDCS
HamD scores and the 2-week follow-up MADRAS scores [F(1,
7)= 59.600; p< 0.0005], indicating a highly significant decrease
in depression scores.
The post-tDCS MADRAS scores differed significantly from the
2-week follow-up MADRAS scores [F(1, 7)= 7.692; p= 0.028],
indicating a further decrease in depression scores in the follow-up
period.
SAFETY
Safety measures included monitoring side effects throughout the
study, systolic and diastolic blood pressure and heart rate before
and after each tDCS session, and MMSE at baseline and at the
completion of the study.
Side effects
No serious adverse events (SAEs) occurred. Several minor non-
serious AEs that occurred during the treatment course or in the
follow-up period can be seen in Table 3. All these minor events
were transient and fully resolved.
Systolic and diastolic blood pressure and heart rate
For each participant, and for each of the 10-days of the tDCS
administration, we examined changes in systolic and diastolic
Table 3 | Adverse events presented in the table in italics were rated by
the study physician as unlikely related or unrelated to the study
procedure.
Event No. of subjects
Unpleasant tingling/prickling sensation under
electrode during one tDCS session
2
Mild dizziness 1
Restlessness 1
Swollen/painful ankles 1
Muscle spasm in thigh 1
Worsening of seasonal allergy 1
Disturbed GI (diarrhea and nausea) 1
Tightness in chest due to asthma 1
Pain in left hip 1
Table 1 |Tests of within-subjects contrasts for HAM-D.
Source Hamilton Type III sum of squares df Mean square F Sig.
Hamilton Pre-tDCS vs. Post-tDCS and 2 weeks later 2450.000 1 2450.000 174.112 0.000
Post-tDCS and 2 weeks later 40.500 1 40.500 2.498 0.158
Error (Hamilton) Pre-tDCS vs. Post-tDCS and 2 weeks later 98.500 7 14.071
Post-tDCS and 2 weeks later 113.500 7 16.214
Table 2 |Tests of within-subjects contrasts for MADRAS.
Source MADRAS Type III sum of squares df Mean square F Sig.
MADRAS Pre-tDCS vs. Post-tDCS and 2 weeks later 2485.125 1 2485.125 59.600 0.000
Post-tDCS and 2 weeks later 144.500 1 144.500 7.692 0.028
Error (MADRAS) Pre-tDCS vs. Post-tDCS and 2 weeks later 291.875 7 41.696
Post-tDCS and 2 weeks later 131.500 7 18.786
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blood pressure and heart rate before and after tDCS adminis-
tration. For systolic and diastolic blood pressure, we considered
a change from pre- to post-tDCS administration to be clinically
significant if it varied by 10 mmHg or more. For heart rate, we
considered a change from pre- to post-tDCS administration to be
clinically significant if the change was 10% or greater.
(a) Clinically significant changes in systolic blood pressure
For the eight participating patients, clinically significant
change in systolic blood pressure varied from −27 to
20 mmHg. All patients had such a significant change on at
least one of the days of tDCS administration, ranging from
1- to 5-days. As can be seen in Table 4, there were 6 clinically
significant increases and 19 clinically significant decreases in
systolic blood pressure.
Regarding the days on which the changes occurred, they
included a change for one of the patients on each of days 6 and
9; for two patients on days 1, 3, 5, and 8; for three patients on
days 2 and 10; for four patients on day 7; and for five patients
on day 4.
(b) Clinically significant changes in diastolic blood pressure
For the eight participating patients, clinically significant
change in diastolic blood pressure varied from −20 to
15 mmHg. Six of the eight patients had such a significant
change on at least one of the days of tDCS administration,
ranging from 1- to 5-days. As can be seen in Table 4, there
were five clinically significant increases and 10 clinically sig-
nificant decreases in diastolic blood pressure. Regarding the
days on which the changes occurred, they included no changes
for any patients on day 2; changes for one patient on days 5, 6,
9, and 10; for two patients on days 1, 3, 7, and 8; and for three
patients on day 4.
(c) Clinically significant changes in heart rate
Each of the eight evaluated subjects had at least 1 day on which
there was a clinically significant change in heart rate, rang-
ing from 1- to 5-days. There were nine clinically significant
increases and 14 clinically significant decreases in heart rate
(Table 4). Regarding the days on which the changes occurred,
they included change for one patient on days 2, 5, 9, and 10;
for two patients on days 3 and 6; for three patients on days 7
and 8; for four patients on day 1; and for five patients on day 4.
Mini-mental state evaluation before and after treatment
Scores for the eight subjects on the MMSE ranged from 20 to 30
(mean= 28; s.d.= 3.02) before the tDCS treatment and from 25
to 30 (mean= 29.0; s.d.= 1.8) at the follow-up. The individual
participant scores remained either unchanged or increased after
the treatment. There was no case of the score-decrease between
the baseline and the end of the study assessment.
ADHERENCE TO THE TREATMENT
Adherence to the treatment was determined as the percentage of
participants who finished the 2-week tDCS treatment course, and
the percentage who completed the entire study, including partici-
pation in the 2-week follow-up. Only two subjects (20%) did not
receive the minimum of required eight tDCS treatment sessions.
Each of the two subjects completed two treatment sessions at the
beginning of the treatment course. Both subjects dropped out due
to a personal-schedule conflict and did not come for the follow-up
evaluation.
Eight subjects (80% of patients) received the required eight
or more treatment sessions. Of these, six subjects did not miss
any treatment sessions, one subject missed one treatment, and
one subject missed two treatments. As the two missed treatments
(last two treatments of the course) for this latter subject were on
consecutive days, the subject as per protocol did not finish the
treatment course and was not considered a completer. However,
all other data and evaluations were collected from this subject
and included in the analysis. Qualitative evaluation of this non-
completer revealed that the subject missed the two sessions due
to the death of family member. The subject’s frequent commu-
nication with the study personnel revealed high motivation to
participate in the study procedures and exhibited behavior typical
for treatment-adherent subjects. If this non-completer is elimi-
nated from the analysis, there were very few substantial changes in
study results. In particular, as was the case with the eight partic-
ipants, the pre-tDCS HamD scores were significantly higher than
the average of the post-tDCS HamD scores and the 2-week follow-
up HamD scores for the seven completers [F(1, 6)= 137.388;
p< 0.0005]. In addition, the pre-tDCS MADRAS scores were sig-
nificantly higher for the seven completers than the average of the
post-tDCS MADRAS scores and the 2-week follow-up MADRAS
scores [F(1, 6)= 72.199; p< 0.0005]. For the seven completers,
Table 4 | Clinically significant change from pre- to post-tDCS administration in systolica and diastolic blood pressurea and heart rateb.
Subject
#2
Subject
#3c
Subject
#4
Subject
#5
Subject
#6
Subject
#7d
Subject
#9
Subject
#10
Total
No. of days of systolic BP increase 2 2 0 1 0 0 1 0 6
No. of days of systolic BP decrease 3 2 2 1 4 4 2 1 19
No. of days of diastolic BP increase 1 0 2 0 1 0 0 1 5
No. of days of diastolic BP decrease 1 1 3 0 3 0 1 1 10
No. of days of heart rate increase 0 0 3 0 2 0 4 0 9
No. of days of heart rate decrease 2 2 1 1 1 3 1 3 14
aA change of 10 mmHg is considered clinically significant.
bA change of 10% is considered clinically significant.
cData on systolic and diastolic blood pressure and heart rate were missing on Day 3.
dData on systolic and diastolic blood pressure and heart rate were not collected on Days 9 and 10 as the subject did not come for the two study visits.
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analyses also indicate duration of the decrease in depressive symp-
toms from immediately post-tDCS to the 2-week follow-up on
both the HamD and the MADRAS. However, although there was
a statistically significant further decline in depressive symptoms
as measured by the MADRAS when the eight participants were
included in the analysis [F(1, 7)= 7.692; p= 0.028], the decline
on the MADRAS was only of borderline significance when only
the seven completers were included [F(1, 6)= 5.250; p= 0.062].
PATIENTS’ SATISFACTION
Patient’s scores on the 4-point (0–3) Satisfaction numerical rating
scale after the last tDCS session as well as at the follow-up ranged
between 2 (satisfied a lot with the results of tDCS treatment) and 3
(fully satisfied). After the last tDCS, six of eight subjects were fully
satisfied with the results, and two subjects were satisfied a lot, mean
score 2.75, s.d. 0.46. At the 2-week follow-up, seven subjects were
fully satisfied and one subject was satisfied a lot, mean score 2.88,
s.d. 0.35, indicating that the level of satisfaction with the results of
the tDCS treatment did not deteriorate during the post-treatment
follow-up period.
PRELIMINARY FINDINGS FROM QUALITATIVE INTERVIEWS
Four themes emerged to describe participants’ experiences with
tDCS: (a) a narrative of frustration and helplessness with previous
depression and medication treatment, (b) the sensory experience
of tDCS, including tingling at site placement and desensitization
to tingling or irritation after the first few treatments, (c) altruism,
with particular attention to improving depression treatment for
other HIV-infected persons, and (d) clearer thinking with reduced
perseveration, rigidity of thinking, and drug cravings.
Subjects who did not complete the treatment indicated a high
motivation to participate in the entire study but said that unantic-
ipated scheduling conflicts prevented them from doing so. They
each suggested that future tDCS treatment protocols be developed
to maximize flexibility for participants (i.e., offering options of
evening and weekend appointments so that subjects could “make
up” a missed session). The subject who received eight sessions of
tDCS said she was noting improvement in her mood and clar-
ity in her thinking. The other two non-completers who received
two treatment sessions did not perceive any changes in depressive
symptoms. The interviews did not reveal any identifiable differ-
ences in the demographic or clinical characteristics of subjects
who completed the treatment compared with non-completers. All
10 participants reported their willingness to participate in future
tDCS clinical trials.
FEASIBILITY OF BIOMARKER-COLLECTION
All study participants agreed to provide samples of blood and saliva
for biochemical analysis of immunity biomarkers. At the time of
collection, all subjects fully cooperated and followed instruction
of study personnel. Data collection of serum and saliva samples
for cytokine assays was feasible in this patient population.
DISCUSSION
This was a pilot, open-label study to determine the feasibility
of using novel tDCS antidepressant treatment in HIV-infected
persons. The study evaluated clinical outcomes, safety, acceptabil-
ity, and patient’s satisfaction with the treatment, as well as the
feasibility of collecting serum and saliva cytokine biomarkers in a
2-week tDCS treatment protocol.
To our knowledge, this is the first study to provide evidence
about the feasibility of the tDCS treatment protocol in an HIV
population, and the first tDCS study applying a mixed methods
approach.
In accordance with the previous tDCS studies in the general
population (Fregni et al., 2006; Boggio et al., 2008a; Rigonatti et al.,
2008; Kalu et al., 2012), the results of our study showed a decrease
of depressive symptoms after tDCS treatment. Although our
study was not sham-controlled, the relief of depressive symptoms
was well beyond effects attributable solely to placebo response
observed in previous studies (Fregni et al., 2006; Boggio et al.,
2008a; Rigonatti et al., 2008; Kalu et al., 2012). Further, it is of
great clinical interest that the improvement of depressive symp-
toms after tDCS in our study did not deteriorate in the 2-week
follow-up period, which provides a rationale for future studies of
durability of tDCS effects.
Further, results of our study contributed to evidence on the
safety of tDCS treatment, as none of our subjects experienced any
SAE; the few non-SAEs that occurred in our study were minor
and transient. Monitoring and evaluation of blood pressure and
heart rate before and after each tDCS session showed occasional
bi-directional changes in these parameters. The changes were not
specific to the study participants with a history and/or present sta-
tus of hypertension, and a decrease of the parameters was observed
more often than an increase. Of note, numerous factors could con-
tribute to the observed changes, including anticipation stress prior
the first tDCS stimulation, physical activity immediately prior
the study visit, or level of relaxation during the 20-min “quiet
time” when receiving tDCS stimulation. The decreasing effect of
tDCS on blood pressure has been previously noted and Cogia-
manian et al. (2010) discussed the potential use of tDCS in the
treatment of hypertension. However, our finding of bi-directional
fluctuation suggests caution and monitoring of blood pressure
and heart rate during tDCS stimulation, and further studies of
tDCS effects.
A gratifying finding in our study was the high adherence of sub-
jects to the study protocol. It could be partially because our study
subjects were completers of an NIH-funded study of HIV patients
(R01 AI070005, ACT 2, PI M.V. Gwadz; Gwadz et al., 2011) that
educated patients on relevant issues concerning research partici-
pation to facilitate minorities’ access to participation in suitable
research trials. The high adherence in our study not only supports
feasibility of the 2-week tDCS treatment protocol and its use in a
future RCT, but also contributes to evidence of validity of the ACT
2 educational intervention.
The findings from the qualitative evaluation of the semi-
structured interviews at the end of the study revealed high satis-
faction with the study and willingness of all subjects to participate
in future tDCS studies. The findings were consistent with previ-
ously reported (Rosedale et al., 2009) patients’ experiences with
the repetitive transcranial magnetic stimulation (rTMS) treat-
ment; participants described intense frustration and helplessness
with previous depression and medication treatment, arguing for
novel treatment approaches (Rosedale et al., 2009). The theme
of electrode placement, tingling, and desensitization to tingling
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or irritation after the first few treatments has been previously
described in the rTMS, but not in the tDCS literature (Ander-
son et al., 2006). Altruism has not been previously described as
a motivating factor for participation in brain stimulation stud-
ies and may have been a particular feature of the ACT 2 group
participants or a particular motivating factor for persons infected
with HIV.
Clearer thinking with reduced perseveration, reduced rigid-
ity of thinking, and reduced drug cravings have been previously
described in the tDCS literature and suggest that tDCS may
enhance acute attention and working memory in people with
depression (Loo, 2012). Notably, attention-enhancement as well
as reduced cravings for specific foods and alcohol has also been
observed in patients treated with tDCS (Boggio et al., 2008b;
Fregni et al., 2008; Kang et al., 2009). This may present enormous
clinical opportunity for the HIV patients who present with high
comorbidity of substance abuse.
Our results also support feasibility of saliva and blood sam-
ple collection for the immunity-biomarker analysis and indicate
an applicability of this procedure in future RCT tDCS protocols
involving HIV-infected subjects.
The major limitations of the study and its findings are (i) the
small sample size that limits generalizability of the results, (ii)
the open-label design of the study, (iii) the trained clinical raters
were not blinded to the study protocol, (iv) the study have not
used parallel versions of MMSE at the post-treatment re-testing,
and therefore an order effect might have contributed to the MMSE
results. As the study was not sham-controlled, a future RCT is war-
ranted before conclusions on effectiveness of tDCS antidepressant
treatment in an HIV population can be drawn.
CONCLUSION
The study demonstrated feasibility of the 2-week tDCS treat-
ment protocol in HIV-infected patients, as well as the feasibility of
study enrollment and satisfactory retention of the subjects which
supports future tDCS studies in this patient population.
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